rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

LJPC

50 Posts
Pagina: «« 1 2 3 | Laatste | Omlaag ↓
  3. [verwijderd] 22 december 2005 15:35

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    LA JOLLA PHARMACEUTICAL COMPANY RECEIVES NASDAQ EXTENSION AND COMPLETES REVERSE STOCK SPLIT

    SAN DIEGO, CA, December 21, 2005 – La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that Nasdaq has granted it an extension of time to comply with Nasdaq's minimum bid price rule. The extension period will allow additional time for the closing price of the Company's common stock to be at least $1.00. If the closing price is at least $1.00 for a minimum of 10 consecutive trading days on or before January 6, 2006, the Company will regain compliance with the minimum bid price rule and maintain its Nasdaq National Market listing.

    The Company also announced today that it has completed its previously announced one-for-five reverse stock split. The reverse stock split was proposed, among other matters, to enable the Company to comply with the Nasdaq minimum bid price rule and was approved by the Company's stockholders on December 12, 2005 at a special meeting of stockholders.

    The reverse stock split caused every five shares of the Company's outstanding common stock to convert automatically into one share of common stock. As a result, upon the effective time of stock split, the number of the Company's shares outstanding decreased by one-fifth and the price of the Company's common stock increased by five times. Effective upon the opening of the market on December 22, 2005, the Company's shares of common stock will trade on a post-reverse stock split basis on The Nasdaq National Market.

    La Jolla Pharmaceutical Company is a biotechnology company developing therapeutics for antibody-mediated autoimmune diseases and inflammation afflicting several million people in the United States and Europe. The Company is developing Riquent® for the treatment of lupus kidney disease, a leading cause of sickness and death in patients with lupus. The Company is also developing small molecules to treat various other autoimmune and inflammatory conditions. The Company’s common stock is traded on The Nasdaq Stock Market under the symbol LJPC. For more information about the Company, visit its Web site: www.ljpc.com.

    Psycho
    heeft nu nog maar 400 aandelen

  5. Bel-chin 22 december 2005 20:17

    • Bel-chin

      Lid sinds: 23 mrt 2005

      Laatste bezoek: 06 jun 2024

    • Aanbevelingen

      Ontvangen: 2

      Gegeven: 6

    •    Aantal posts: 188

    quote:

    Alex-prf8s schreef:

    Geen handel in la jolla?
    Toch wel, maar tijdelijk onder het symbool LJPCD omdat de 5:1 RS in uitvoering is.

    P.
  6. Bel-chin 10 januari 2006 20:07

    • Bel-chin

      Lid sinds: 23 mrt 2005

      Laatste bezoek: 06 jun 2024

    • Aanbevelingen

      Ontvangen: 2

      Gegeven: 6

    •    Aantal posts: 188

    Zit er nog iemand in La Jolla? Lijkt zich mooi te herstellen na het diepe afglijden volgend op de reverse split. Wat zijn jullie verwachtingen?

    P.
  7. [verwijderd] 10 januari 2006 20:10

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Bel-chin schreef:

    Zit er nog iemand in La Jolla? Lijkt zich mooi te herstellen na het diepe afglijden volgend op de reverse split. Wat zijn jullie verwachtingen?

    P.
    Niet meer. Bij het afsluiten van het jaar de 2 RS-fondsen opgeruimd: Mcet en La Toya.
    Kijk het aan voordat ik weer instap.

    Psycho
  8. [verwijderd] 13 januari 2006 12:02

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    La Jolla Pharmaceutical in Full Compliance With Nasdaq Listing Requirements
    1/12/2006 11:43:07 AM





    SAN DIEGO, Jan 12, 2006 /PRNewswire-FirstCall via COMTEX/ -- La Jolla Pharmaceutical Company (LJPC) announced today that it has been notified by Nasdaq that the Company has regained compliance with Nasdaq's minimum bid price rule. The Company is now in full compliance with all continued listing requirements.

    La Jolla Pharmaceutical Company is a biotechnology company developing therapeutics for antibody.mediated autoimmune diseases and inflammation afflicting several million people in the United States and Europe. The Company is developing Riquent(R) for the treatment of lupus kidney disease, a leading cause of sickness and death in patients with lupus. The Company is also developing small molecules to treat various other autoimmune and inflammatory conditions. The Company's common stock is traded on The Nasdaq Stock Market under the symbol LJPC. For more information about the Company, visit its Web site: www.ljpc.com.

    Except for historical statements, this press release contains forward- looking statements. These forward-looking statements involve risks and uncertainties, and a number of factors, both foreseen and unforeseen, could cause actual results or events to differ materially from those anticipated. Readers are cautioned to not place undue reliance upon forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date hereof. Interested parties are urged to review the risks described in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, and in other reports and registration statements that we file with the Securities and Exchange Commission from time to time.

    SOURCE La Jolla Pharmaceutical Company
50 Posts
Pagina: «« 1 2 3 | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.120
AB InBev 2 5.538
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.177
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.859
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.840
Aedifica 3 926
Aegon 3.258 323.075
AFC Ajax 538 7.089
Affimed NV 2 6.305
ageas 5.844 109.905
Agfa-Gevaert 14 2.063
Ahold 3.538 74.353
Air France - KLM 1.025 35.293
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.050
Alfen 16 25.282
Allfunds Group 4 1.517
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 421
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.915
AMG 971 134.362
AMS 3 73
Amsterdam Commodities 305 6.745
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 496
Antonov 22.632 153.605
Aperam 92 15.059
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.806
Arcelor Mittal 2.034 320.988
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.355
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.614
ASML 1.766 110.178
ASR Nederland 21 4.512
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.940
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449